BFM
INMB icon

Boothbay Fund Management’s INmune Bio INMB Stock Holding History

Boothbay Fund Management’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-24,158
Closed -$424K – 2039
2021
Q2 		$424K Sell
24,158
-7,912
-25% -$107K 0.01% 1092
2021
Q1 		$381K Buy
32,070
+8,909
+38% +$160K 0.01% 1082
2020
Q4 		$399K Buy
+23,161
New +$218K 0.01% 839

Other funds holding INMB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Boothbay Fund Management's INMB Position: Q3 2021 in Review

Boothbay Fund Management sold out of INmune Bio (INMB) in Q3 2021, closing a stake of 24,158 shares — an estimated $424K sold.

Boothbay Fund Management first reported a position in INMB in Q4 2020 and held it in 3 quarters. The position peaked at $424K in Q2 2021. 41 funds tracked by Wall St. Rank hold INMB as of Q3 2021.

  • Boothbay Fund Management reported no remaining INmune Bio position as of Q3 2021 after selling out during the quarter.
  • Boothbay Fund Management sold 24,158 INmune Bio shares in Q3 2021, an estimated $424K.
  • Boothbay Fund Management first reported a position in INmune Bio in Q4 2020 and held it in 3 quarters.
  • Boothbay Fund Management's INmune Bio position peaked at $424K in Q2 2021.
  • 41 funds tracked by Wall St. Rank held INmune Bio as of Q3 2021.

Based on Boothbay Fund Management's 13F filing for Q3 2021, filed 15 Nov 2021.